Gilead's three-drug HIV regimen wins European panel approval

(Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

from Reuters: Health News https://ift.tt/2r3l9xM